On January 26, 2022 Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, reported that Rick Fair, President and CEO, will participate in the B. Riley Securities 2022 Virtual Oncology Conference (Press release, Bellicum Pharmaceuticals, JAN 26, 2022, View Source [SID1234607402]). A corporate presentation is scheduled for Thursday, January 27, 2022 at 4 p.m. ET / 1 p.m. PT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available from the Investor Relations section of the company website at Events & Presentations – Bellicum with a replay available shortly after the live event.